Clin Drug Investig. 2024 Jul;44(7):513-525. Also presented at ESMO Asia Congress 2023. [Acknowledged for medical writing assistance]
#MarksManInsights
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study
by